Business Context and Reporting Period
Company: Bristol-Myers Squibb Company (BMS)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2006
Business Overview: BMS is a global pharmaceutical and healthcare company organized into three reportable segments: Pharmaceuticals (77% of 2006 sales), Nutritionals (13%), and Other Health Care (10%). The company focuses on the discovery, development, and marketing of innovative pharmaceuticals, infant nutrition, and medical devices.
Key Financial Metrics
| Metric | 2006 | 2005 | Change |
|---|---|---|---|
| Net Sales | $17,914 million | $19,207 million | (7)% |
| Net Earnings | $1,585 million | $3,000 million | (47)% |
| Earnings Per Share (Diluted) | $0.81 | $1.52 | (47)% |
| Operating Cash Flow | $2,083 million | $1,836 million | 14% |
| Total Assets | $25,575 million | $28,138 million | (9)% |
| Long-Term Debt | $7,248 million | $8,364 million | (13)% |
| Working Capital | $3,806 million | $5,393 million | (29)% |
Margins: Gross margin decreased to 66.8% in 2006 from 69.1% in 2005. Net income margin declined to 8.8% from 15.6%.
Material Changes vs. Prior Period
- Revenue Decline: Net sales decreased 7% primarily due to the loss of market exclusivity for PRAVACHOL (pravastatin) in the U.S. and Europe, and a significant adverse impact on PLAVIX* sales caused by the at-risk launch of a generic competitor by Apotex in August 2006.
- Profitability Impact: Net earnings dropped 47% due to lower sales, a $353 million increase in litigation reserves (pricing and sales practices), and $220 million in debt retirement costs. These were partially offset by a $200 million gain on the sale of the DOVONEX* asset.
- Product Performance: While PLAVIX* sales fell 15% and PRAVACHOL fell 47%, growth drivers such as ABILIFY* (+41%), ERBITUX* (+58%), and REYATAZ (+34%) showed strong performance.
- Debt Restructuring: The company retired $2.5 billion of 5.75% Notes due 2011 and issued new debt instruments, incurring significant pre-tax expenses related to early redemption and interest rate swap terminations.
Guidance, Outlook, and Risks
- 2007 Outlook: Management expects net sales reductions from exclusivity losses to moderate to a range of $0.9 billion to $1.0 billion (down from $1.4 billion in 2006). Gross margins are expected to improve due to a higher mix of growth products and manufacturing efficiencies.
- PLAVIX* Litigation Risk: The outcome of the patent litigation with Apotex remains uncertain. If Apotex prevails, the company expects renewed generic competition, which could be material to sales, cash flows, and financial condition. The company estimates the 2006 generic launch impact at $1.2 billion to $1.4 billion.
- Legal Contingencies: The company faces significant pending lawsuits and investigations regarding pricing, sales practices, and product liability. Management believes the aggregate impact beyond current reserves is reasonably likely to be material to future results.
- Deferred Tax Assets: Realization of significant foreign tax credit and research tax credit carryforwards depends on future domestic taxable income. Renewed generic competition for PLAVIX* could necessitate valuation allowances against these assets.
Investor Verification Checklist
- PLAVIX* Litigation Status: Monitor the final ruling in the Apotex patent infringement trial and any subsequent generic market entry.
- Litigation Reserve Adequacy: Verify the sufficiency of the $499 million reserve established for pricing and sales practice investigations.
- Deferred Tax Asset Realization: Assess the company's ability to generate sufficient domestic income to utilize foreign tax credit and R&D carryforwards expiring beginning in 2012.
- Biologics Manufacturing Capacity: Track progress on the new $750 million biologics facility in Devens, Massachusetts, critical for future product launches like ORENCIA.
- Exclusivity Losses: Confirm the actual sales impact of PRAVACHOL and other products losing exclusivity in 2007 against the $0.9-$1.0 billion guidance range.